NCT00336817View on ClinicalTrials.gov

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Immunosuppression
Interventions
DRUG

Myfortic

Myfortic 360mg or 720 mg BID for 90 days

DRUG

CellCept

CellCept 500mg or 1000mg BID for 90 days

Trial Locations (1)

15213

University of Pittsburgh Medical Center, Pittsburgh

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Pittsburgh

OTHER